[{"id":"6b86dd16-913f-4c78-bcba-295630147d99","acronym":"","url":"https://clinicaltrials.gov/study/NCT02587689","created_at":"2021-01-18T12:33:16.714Z","updated_at":"2024-07-02T16:37:27.283Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor","source_id_and_acronym":"NCT02587689","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" HER-2 • ER • ALK • PGR","pipe":" | ","alterations":" EGFR mutation • HER-2 negative • ER negative • ALK translocation • MUC1 expression","tags":["HER-2 • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 negative • ER negative • ALK translocation • MUC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-MUC1 CAR-T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2016-12-05"}]